Ocuphire Pharma Results

APX3330 - Novel and Dual-Acting MOA in an Oral Pill Ref-1 Involved in Multiple Key Pathways that Contribute to Diabetic Retinopathy and DME LucentisⓇ EYLEAⓇ Mechanism of Action - Ref-1 Inhibition PHARMA Hypoxia ↓ Ref-1 HIF-1a VEGF (Signaling Cascade) Anti-VEGF APX3330 Neovascularization Inflammation ↓ Ref-1 ↓ NF-kB ↓ TNF-a Chemokines Other Growth Factors (Signaling Cascade) Steroids ● • APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of Ref-1 ● Ref-1 (reduction-oxidation effector factor-1) is a novel target discovered by Dr. Mark R. Kelley at Indiana University School of Medicine ● APX3330 previously developed by Eisai for multiple hepatic inflammatory indications and later by Apexian for advanced solid tumors Similar oncology origin as approved anti-VEGFs MOA uniquely decreases both abnormal angiogenesis and inflammation by blocking pathways downstream of Ref-1 - Logsdon et al (2018), Li et al (2014). Ocuphire Rangasamy S, McGuire PG, Das A. Middle East Afr J Ophthalmol 2012;19:52-59; Sohn HJ et al. Am J Ophthalmol 2011;152:686-694. 32

View entire presentation